A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Clinical trial NCT03677596 · COMPLETED

Trial details

NCT number: NCT03677596
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Leukemia Precursor b-Cell Lymphoblastic Leukemia-Lymphoma ACUTE LYMPHOBLASTIC LEUKEMIA

Start date: 2019-07-01
Primary completion: 2022-09-21
Enrollment: 102

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.